argenx NV ADR (ARGX)vsCytokinetics Inc (CYTK)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $56.45B
CYTK
Cytokinetics Inc
$80.01
+1.49%
HEALTHCARE · Cap: $9.52B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 4382% more annual revenue ($4.74B vs $105.81M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CYTK
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$891.32
$1313.01 discount
Margin of Safety
-27.5%
Fair Value
$61.78
Current Price
$80.01
$18.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 1126.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 188.4x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -572.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : CYTK
The strongest argument for CYTK centers on Revenue Growth, Debt/Equity. Revenue growth of 1126.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : CYTK
The primary concerns for CYTK are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CYTK is a hypergrowth play — different risk/reward profiles.
CYTK carries more volatility with a beta of 0.43 — expect wider price swings.
CYTK is growing revenue faster at 1126.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 32/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Cytokinetics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?